Early-stage oncology The company is a clinical-stage biopharma with an anti-cancer compound Kevetrin and a focus on oncology, suggesting opportunities in strategic partnerships, licensing discussions, and collaboration with oncology-focused CROs and research institutions.

Dermatology and infections In addition to cancer, the pipeline includes Prurisol for psoriasis and Brilacidin for skin infections and mucositis prevention, indicating potential cross-sell or co-development discussions with dermatology and infectious disease networks.

Small company dynamics With a lean team and early-stage funding signals (low revenue, limited employees), there is a need for scalable partnerships, contract manufacturing, and advisory or investment engagement from larger pharmaceutical or venture partners.

IP and asset focus The portfolio comprises multiple drug candidates with proprietary mechanisms (defensin-mimetic Brilacidin and small molecules), presenting partner-friendly opportunities for out-licensing, co-development, or milestone-driven deals.

Clinical-stage advancement Active emphasis on clinical trials for cancer, psoriasis, and mucositis-related indications suggests sales potential in CRO services, regulatory consulting, and pharmacovigilance support as the company advances its assets.